Interaction of p53 with Its Consensus DNA-Binding Site

REFERENCES

• Bargonetti, J., P. N. Friedman, S. E. Kern, B. Vogelstein, and C. Prives. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091.
   PubMed Web of Science ®Google Scholar
• Bargonetti, J., J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565–2574.
   PubMed Web of Science ®Google Scholar
• Cho, Y. J., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumori-genic mutations. Science 265:346–355.
   PubMed Web of Science ®Google Scholar
• Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A. M. Gronenborn. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386–391.
   PubMedGoogle Scholar
• Demczuk, S., M. Harbers, and B. Vennstrom. 1993. Identification and analysis of all components of a gel retardation assay by combination with immu-noblotting. Proc. Natl. Acad. Sci. USA 90:2574–2578.
   PubMed Web of Science ®Google Scholar
• Donehower, L. A., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:181–205.
   PubMed Web of Science ®Google Scholar
• Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (London) 356:215–221.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Human genomic DNA sequences define a consensus DNA binding site for p53. Nat. Genet. 1:45–49.
   PubMed Web of Science ®Google Scholar
• Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358: 83–86.
   PubMed Web of Science ®Google Scholar
• Fields, S., and S. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049.
   PubMed Web of Science ®Google Scholar
• Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866–2871.
   PubMed Web of Science ®Google Scholar
• Halazonetis, T. D., L. J. Davis, and A. N. Kandil. 1993. Wild-type p53 adopts a mutant-like conformation when bound to DNA. EMBO J. 12:1021–1028.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551–3555.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tet-ramers. Curr. Biol. 4:865–875.
   PubMedGoogle Scholar
• Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830.
   PubMed Web of Science ®Google Scholar
• Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556–2564.
   PubMed Web of Science ®Google Scholar
• Pennica, D., D. V. Goeddel, J. S. Hayflick, N. C. Reich, C. W. Anderson, and A. J. Levine. 1984. The amino acid sequence of murine p53 determined from a c-DNA clone. Virology 134:477–482.
   PubMedGoogle Scholar
• Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91:1998–2002.
   PubMed Web of Science ®Google Scholar
• Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051.
   PubMed Web of Science ®Google Scholar
• Reed, M., Y. Wang, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: suppression, transformation, and transacti-vation. Gene Expr. 3:95–107.
   PubMedGoogle Scholar
• Shaulian, E., A. Zauberman, J. Milner, E. A. Davies, and M. Oren. 1993. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J. 12:2789–2797.
   PubMedGoogle Scholar
• Slingerland, J. M., J. R. Jenkins, and S. Benchimol. 1993. The transforming and suppressor functions of p53 alleles—effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 12: 1029–1037.
   PubMed Web of Science ®Google Scholar
• Stenger, J. E., G. A. Mayr, K. Mann, and P. Tegtmeyer. 1992. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 5:102–106.
   PubMedGoogle Scholar
• Stenger, J. E., P. Tegtmeyer, G. A. Mayr, M. Reed, Y. Wang, P. Wang, and P. V. C. Hough. 1994. p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J. 13:6011–6020.
   PubMedGoogle Scholar
• Tarunina, M., and J. R. Jenkins. 1993. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 8:3165–3173.
   PubMedGoogle Scholar
• Tokino, T., S. Thiagalingam, W. S. El-Deiry, T. Waldman, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3:1537–1542.
   PubMedGoogle Scholar
• Unger, T., J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley. 1993. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol. 13:5186–5194.
   PubMedGoogle Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Wang, P., M. Reed, Y. Wang, G. Mayr, J. E. Stenger, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14:5182–5191.
   PubMed Web of Science ®Google Scholar
• Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and charac-terization of two autonomous DNA-binding regions. Genes Dev. 7:2575–2586.
   PubMedGoogle Scholar
• Zambetti, G. P., and A. J. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:855–865.
   PubMed Web of Science ®Google Scholar